Πλοήγηση ανά Θέμα "B Raf kinase inhibitor"

Αποτελέσματα 1-2 από 2

Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK Activation

Beneker C.M., Rovoli M., Kontopidis G., Röring M., Galda S., Braun S., Brummer T., McInnes C. (2019)

Despite the clinical success of BRAF inhibitors like vemurafenib in treating metastatic melanoma, resistance has emerged through "paradoxical MEK/ERK signaling" where transactivation of one protomer occurs as a result of ...
Oligometastasis and local ablation in the era of systemic targeted and immunotherapy

Mazzola R., Jereczek-Fossa B.A., Franceschini D., Tubin S., Filippi A.R., Tolia M., Lancia A., Minniti G., Corradini S., Arcangeli S., Scorsetti M., Alongi F. (2020)

Background: During these last years, new agents have dramatically improved the survival of the metastatic patients. Oligometastases represent a continuous field of interest in which the integration of metastases-directed ...